Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16785992 
Winograd-Katz SE, Levitzki A (2006) Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25, 7381-90 16785992
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T693-p - EGFR (human)
Orthologous residues
EGFR (human): T693‑p, EGFR iso5 (human): T693‑p, EGFR (mouse): T695‑p, EGFR (rat): T694‑p, EGFR (pig): T693‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  CHO-K1 (fibroblast), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
SB202190 cisplatin inhibit treatment-induced increase
U0126 cisplatin no effect upon treatment-induced increase
SB600125 cisplatin no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  receptor internalization, altered

T308-p - Akt1 (rat)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), MDA-MB468 (breast cell), OVCAR3 (ovarian), PANC-1 (pancreatic), Rat1 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
cisplatin increase
LY294002 cisplatin inhibit treatment-induced increase
AG1478 cisplatin inhibit treatment-induced increase at 1 microM concentration AG1478
AG1478 cisplatin no effect upon treatment-induced increase at 100 nM concentration of AG1478
PP1 cisplatin no effect upon treatment-induced increase at 10 microM concentration PP1
PP1 cisplatin inhibit treatment-induced increase at 20 microM concentration PP1

S473-p - Akt1 (rat)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
LY294002 cisplatin inhibit treatment-induced increase
cisplatin increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.